1. Home
  2. LMAT vs ADPT Comparison

LMAT vs ADPT Comparison

Compare LMAT & ADPT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo LeMaitre Vascular Inc.

LMAT

LeMaitre Vascular Inc.

HOLD

Current Price

$94.30

Market Cap

2.1B

Sector

Health Care

ML Signal

HOLD

Logo Adaptive Biotechnologies Corporation

ADPT

Adaptive Biotechnologies Corporation

HOLD

Current Price

$20.70

Market Cap

2.7B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
LMAT
ADPT
Founded
1983
2009
Country
United States
United States
Employees
N/A
N/A
Industry
Medical/Dental Instruments
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
2.1B
2.7B
IPO Year
2006
2019

Fundamental Metrics

Financial Performance
Metric
LMAT
ADPT
Price
$94.30
$20.70
Analyst Decision
Buy
Strong Buy
Analyst Count
5
9
Target Price
$105.80
$17.78
AVG Volume (30 Days)
292.9K
3.4M
Earning Date
05-05-2026
05-05-2026
Dividend Yield
0.93%
N/A
EPS Growth
30.57
63.89
EPS
0.68
N/A
Revenue
$249,602,000.00
$276,976,000.00
Revenue This Year
$14.21
$3.98
Revenue Next Year
$8.88
$22.72
P/E Ratio
$138.13
N/A
Revenue Growth
13.53
54.77
52 Week Low
$79.01
$9.96
52 Week High
$118.01
$20.76

Technical Indicators

Market Signals
Indicator
LMAT
ADPT
Relative Strength Index (RSI) 47.80 71.02
Support Level $82.26 $15.08
Resistance Level $97.83 N/A
Average True Range (ATR) 3.02 1.33
MACD 0.63 0.28
Stochastic Oscillator 61.26 93.68

Price Performance

Historical Comparison
LMAT
ADPT

About LMAT LeMaitre Vascular Inc.

LeMaitre Vascular Inc is a provider of medical devices and human tissue cryopreservation services mainly used in the treatment of peripheral vascular disease, end-stage renal disease, and cardiovascular disease. The company develops, manufactures, and markets vascular devices to address the needs of vascular surgeons and, to a lesser extent, other specialties such as cardiac surgeons, general surgeons, and neurosurgeons. Its diversified portfolio consists of branded products used in arteries and veins that are well known to vascular surgeons. It operates across the Americas, Europe, the Middle East and Africa, and Asia Pacific, with the majority of its revenue generated from the Americas.

About ADPT Adaptive Biotechnologies Corporation

Adaptive Biotechnologies Corp is a company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is a test authorized by the FDA for the detection and monitoring of minimal residual disease (MRD) in patients with multiple myeloma (MM), B cell acute lymphoblastic leukemia (ALL) and chronic lymphocytic leukemia (CLL) and is also available as a CLIA-validated laboratory developed test (LDT) for patients with other lymphoid cancers. The company has two operating segments: Minimal Residual Disease and Immune Medicine. The company generates the majority of its revenue from the Minimal Residual Disease segment.

Share on Social Networks: